Literature DB >> 19759410

Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging.

D Minarik1, M Ljungberg, P Segars, K Sjögreen Gleisner.   

Abstract

With high-dose administration of (90)Y labeled antibodies, it is possible to image (90)Y without an admixture of (111)In. We have earlier shown that it is possible to perform quantitative (90)Y bremsstrahlung SPECT for dosimetry purposes with reasonable accuracy. However, whole-body (WB) activity quantification with the conjugate view method is not as time consuming as SPECT and has been the method of choice for dosimetry. We have investigated the possibility of using a conjugate view method where scatter-, backscatter- and septal-penetration compensations are performed by inverse filtering and attenuation correction is performed with a WB x-ray image, for total-body and organ activity quantification of (90)Y. The method was evaluated using both Monte Carlo simulated scintillation camera images using realistic source distributions, and by an experimental phantom study. The method was evaluated in terms of image quality and accuracy of the activity quantification. The experimental phantom study was performed using the RSD torso phantom with (90)Y activity uniformly distributed in the liver insert. A GE Discovery VH/Hawkeye system was used to acquire the image. The simulation study was performed for a realistic activity distribution in the NCAT anthropomorphic phantom where (90)Y bremsstrahlung images were generated using the SIMIND MC program. Two different phantom configurations and two activity distributions were simulated. To mimic the RSD phantom experiment one simulation study was also made with (90)Y activity located only in the liver. The SIMIND program was configured to resemble a GE Discovery VH/Hawkeye system. An x-ray projector program was used to generate whole-body x-ray images from the NCAT phantom for attenuation correction in the conjugate view method. Organ activities were calculated from ROIs that exactly covered the organs. Corrections for background activity, overlapping activity and source extension in the depth direction were applied on the ROI data. The total-body activities for the simulated images were generally overestimated by around 10%, which is reasonable since the correction for source extension was not applied on the total-body values. The accuracy of the organ activities was mostly within 15% for both the simulation study and the experimental study. The results suggest that it is possible to quantify (90)Y activity in ROIs with reasonable accuracy using this method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759410     DOI: 10.1088/0031-9155/54/19/014

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  17 in total

Review 1.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

Review 2.  Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Authors:  Youngho Seo
Journal:  Nucl Med Mol Imaging       Date:  2019-02-18

Review 3.  Yttrium-labelled peptides for therapy of NET.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara M Grana; Marco Chinol; Silvia M Baio; Stefano Severi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 4.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

5.  Development of a model of the coronary arterial tree for the 4D XCAT phantom.

Authors:  George S K Fung; W Paul Segars; Grant T Gullberg; Benjamin M W Tsui
Journal:  Phys Med Biol       Date:  2011-08-10       Impact factor: 3.609

6.  Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.

Authors:  C Arrichiello; L Aloj; M Mormile; L D'Ambrosio; F Frigeri; C Caracò; M Arcamone; F De Martinis; A Pinto; S Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

7.  The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects.

Authors:  Hojjat Ahmadzadehfar; Marianne Muckle; Amir Sabet; Kai Wilhelm; Christiane Kuhl; Kim Biermann; Torjan Haslerud; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

8.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Authors:  L Bodei; J Mueller-Brand; R P Baum; M E Pavel; D Hörsch; M S O'Dorisio; T M O'Dorisio; T M O'Dorisiol; J R Howe; M Cremonesi; D J Kwekkeboom; John J Zaknun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05       Impact factor: 9.236

9.  Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization.

Authors:  Mattijs Elschot; Johannes Franciscus Wilhelmus Nijsen; Alida Johanna Dam; Hugo Wilhelmus Antonius Maria de Jong
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

10.  Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization.

Authors:  Mattijs Elschot; Bart J Vermolen; Marnix G E H Lam; Bart de Keizer; Maurice A A J van den Bosch; Hugo W A M de Jong
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.